Results 71 to 80 of about 3,285,062 (216)

Drug modulation of activity of microRNA generation in functional disorders of the gallbladder and sphincter of Oddi in children

open access: yesZdorovʹe Rebenka, 2019
Background. Functional disorders of the gallbladder and sphincter of Oddi are highly relevant in pediatric gastroenterology. The purpose of the study was to improve the treatment for functional disorders of the gallbladder and sphincter of Oddi in ...
A.E. Abaturov, V.L. Babich
doaj   +1 more source

Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis [PDF]

open access: yesVojnosanitetski Pregled, 2009
Background. Amyloidosis represents a group of different diseases characterized by extracellular accumulation of pathologic fibrillar proteins in various tissues and organs.
Faust Dominik   +3 more
doaj   +1 more source

Hepatic Sinusoidal Obstruction Syndrome Induced by Pyrrolizidine Alkaloids: Mechanistic Insights, Emerging Biomarkers, and Therapeutic Innovations

open access: yesiNew Medicine, EarlyView.
ABSTRACT Hepatic sinusoidal obstruction syndrome (HSOS) is a microcirculatory disorder of the liver that poses a serious threat to human health. Pyrrolizidine alkaloids (PAs), a class of toxins widely found in plants, are often ingested accidentally and are one of the major causes of HSOS.
Fumin Zhang   +7 more
wiley   +1 more source

A hepatic enigma: Pediatric presentation of primary biliary cholangitis

open access: yesJPGN Reports, EarlyView.
Abstract Primary biliary cholangitis (PBC) is a chronic autoimmune condition characterized by destruction of intrahepatic bile ducts, leading to fibrosis and cirrhosis of the liver. It is an extremely rare pediatric disease with very few pediatric cases reported to date. Here, we report the case of a 14‐year‐old female who presented with elevated liver
Sindhura Kasturi   +3 more
wiley   +1 more source

A case of idiopathic GGT elevation with acute hepatitis A

open access: yesJournal of Family Medicine and Primary Care, 2019
Ursodeoxycholic acid modifies the bile acid pool and its effect on lowering liver enzymes is well documented in certain cases like chronic hepatitis but on the other hand it is known to worsen when given in advanced stages of liver disease.
Jaspreet Singh   +2 more
doaj   +1 more source

Effects of post‐hepatic portoenterostomy adjuvant therapy on liver transplantation in children with biliary atresia: A systematic review

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Biliary atresia (BA) is a cholangiopathy characterized by obstruction of the intrahepatic and extrahepatic bile ducts. Hepatic portoenterostomy (HPE) is the primary palliative treatment and there is still an urgent need to improve post‐HPE management.
Bianca Ferraz de Almeida Silva   +7 more
wiley   +1 more source

Drug reaction to ursodeoxycholic acid: Lichenoid drug eruption in an infant using ursodeoxycholic acid for neonatal hepatitis

open access: yes, 2002
Lichenoid drug eruptions are skin reactions associated With a number of drugs and chemicals. They are rare in infants. We report here an infant who presented with neonatal hepatitis and who was being treated with ursodeoxycholic acid.
Buyukgebiz, B   +4 more
core   +1 more source

Normal cholestanol in a genetically confirmed cerebrotendious xanthomatosis case presenting as neonatal jaundice

open access: yesJPGN Reports, EarlyView.
Abstract Cerebrotendinous xanthomatosis (CTX) is a treatable genetic disorder associated with deficiency of the sterol 27‐hydroxylase enzyme (CYP27A1), important in bile acid synthesis. CTX may present in the newborn period as hepatic jaundice/cholestasis, that can resolve or can progress to fatal liver disease.
Andrea E. DeBarber   +3 more
wiley   +1 more source

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study

open access: yes, 1992
Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid.
A. Crosignani   +7 more
core   +1 more source

Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment

open access: yesBMC Gastroenterology
Background Ursodeoxycholic acid is the preferred first-line therapy for primary biliary cholangitis. Alternative therapies, such as obeticholic acid, are recommended for patients who cannot tolerate ursodeoxycholic acid or who have an inadequate response
Nicholas MacDonald   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy